Latest GLP-1 Therapies Research Papers

yesterday • Cardiovascular drugs and therapy

Liraglutide may reduce atrial fibrillation by boosting fat tissue signals around the heartLiraglutide Ameliorates Atrial Fibrillation in Association with Enhanced Adiponectin Signaling in Epicardial Adipose Tissue.

Article

yesterday • Journal of cardiothoracic and vascular anesthesia

Guidelines for Treating Heart Failure with Normal Pumping Strength and What They Mean for Heart and Blood Vessel AnesthesiaThe 2026 American College of Cardiology Expert Consensus Decision Pathway for Heart Failure with Preserved Ejection Fraction: Implications for Cardiothoracic and Vascular Anesthesia.

📖 Top 30% JournalArticle

yesterday • Frontiers in endocrinology

Using Artificial Intelligence in Obesity Care: Current Evidence, Missing Links, and Key Steps for PracticeArtificial intelligence in obesity management: clinical evidence, translational gaps, and implementation priorities-a structured narrative review.

🎖️ Top 10% JournalArticle

yesterday • Frontiers in pharmacology

Risk of tumors with semaglutide treatment in people with type 2 diabetes: a review and combined analysis of clinical trialsRisk of neoplasms with semaglutide in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials.

📖 Top 20% JournalSystematic Review

yesterday • Diabetology & metabolic syndrome

Effects of GLP-1 and GLP-1/GIP receptor drugs before, during, and after pregnancyImpact of GLP-1 and GLP-1/GIP receptor agonists before, during, and after pregnancy: a narrative review.

📖 Top 20% JournalArticle

yesterday • JCEM case reports

Repeated eyelid bumps linked to tirzepatide treatment: a case seriesSimultaneous and recurrent hordeola and chalazia associated with tirzepatide therapy: a case series.

Case Reports

yesterday • Diabetologia

Single molecule activating GLP-1 and APJ receptors improves metabolism, reduces abnormal blood fats, and normalizes liver fat and enzyme levels in high-fat diet miceUnimolecular GLP-1/APJ receptor co-agonism improves metabolism and dyslipidaemia as well as normalising hepatic triglyceride and aminotransferase elevation in high-fat-fed mice.

🥈 Top 2% JournalArticle

yesterday • Diabetes, obesity & metabolism

How Safe and Effective BGM0504 Is and How It Acts in the Body in Overweight or Obese Chinese Adults Without DiabetesEffectiveness, Safety and Pharmacokinetics of BGM0504, a Dual GLP-1/GIP Receptor Agonist, in Chinese Adults With Overweight or Obesity Without Diabetes: A Phase 2 Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial.

Article

yesterday • Obesity research & clinical practice

How Epigenetic Changes and Diet Together Influence Response to GLP-1Epigenetic determinants of GLP-1 responsiveness: Integrating dietary modulation beyond genetics.

📖 Top 20% JournalArticle

yesterday • Frontiers in endocrinology

Semaglutide's effectiveness and safety for weight loss and excessive hunger in adults with Prader-Willi syndromeEfficacy and safety of semaglutide for obesity and hyperphagia in adults with Prader-Willi syndrome.

🎖️ Top 10% JournalObservational Study

yesterday • Diabetes, obesity & metabolism

How adults and children with obesity stick to GLP-1 receptor agonist treatments over timeReal-World Adherence Trajectories of GLP-1 Receptor Agonists Among Adults and Paediatric Patients With Obesity.

Article

yesterday • Therapeutic advances in endocrinology and metabolism

Quality and trustworthiness of health information about GLP-1 diabetes drugs on TikTok and BilibiliAssessing the quality and reliability of health information on GLP-1 receptor agonists on TikTok and Bilibili: a cross-sectional analysis of the public health infodemic.

🎖️ Top 10% JournalArticle

yesterday • PloS one

Different effects of semaglutide and CRV431 combined treatment on liver scarring and liver cancer in a fatty liver disease mouse modelDivergent effects of semaglutide and CRV431 Co-therapy on liver fibrosis and HCC in MASLD mouse model.

📖 Top 30% JournalArticle

yesterday • Therapeutic advances in reproductive health

Obesity and weight-loss treatments using GLP-1 in patients cared for by women's health doctorsThe clinical relevance of obesity and glucagon-like peptide-1-based therapies for chronic weight management in patients treated by obstetrician-gynecologists and gynecologists: A non-systematic narrative review.

Article

yesterday • British journal of clinical pharmacology

Using GLP-1 and related drugs to treat heart, liver, and metabolism problems in fatty liver diseaseTargeting the cardiohepatic-metabolic axis: GLP-1-based and incretin multi-agonist therapies in MASH.

📖 Top 20% JournalArticle

2 days ago • Diabetes therapy : research, treatment and education of diabetes and related disorders

Patient Experiences with Tirzepatide and Dulaglutide for Type 2 Diabetes in the SURPASS-CVOT TrialExit Interviews Examining Patient Experiences with Tirzepatide and Dulaglutide for Treatment of Type 2 Diabetes in the SURPASS-CVOT Trial.

📖 Top 20% JournalArticle

2 days ago • Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition

How a GLP-1 receptor activator may influence food intakeEffect of GLP-1 receptor agonist on nutrient intake: A narrative review.

📖 Top 30% JournalArticle

2 days ago • Heart rhythm

How Two Diabetes Medicines Alone or Together May Affect Atrial Fibrillation Return and Heart Health After Ablation TreatmentThe Effect of Glucagon-Like Peptide-1 Receptor Agonists versus Sodium-Glucose Cotransporter-2 Inhibitors Alone and in Combination on AF Recurrence and Cardiovascular Outcomes after Catheter Ablation for Atrial Fibrillation.

🥉 Top 5% JournalArticle

2 days ago • International journal of spine surgery

Do Diabetes Drugs Affect Recovery After Lower Back Fusion Surgery? A Review and AnalysisDo Preoperative Glucagon-Like Peptide-1 Receptor Agonists Influence Lumbar Fusion Outcomes? A Systematic Review and Meta-Analysis.

📖 Top 30% JournalArticle

2 days ago • Diabetes therapy : research, treatment and education of diabetes and related disorders

Heart health outcomes in adults with type 2 diabetes and artery disease starting oral semaglutide versus other non-insulin diabetes medicinesComparing Cardiovascular Outcomes in New Users of Oral Semaglutide Versus Other Noninsulin Glucose-Lowering Therapies Among Adults with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease.

📖 Top 20% JournalArticle

2 days ago • Drug and alcohol dependence reports

Treating opioid and alcohol use disorders together in the US from 1960 to 2026 during the rise of GLP-1 based therapiesCo-treating opioid and alcohol use disorders in the United States, 1960-2026: A historical policy review in the glucagon-like peptide-1 (GLP-1) era.

Article

2 days ago • Advances in nutrition (Bethesda, Md.)

Epigenetic Memory May Explain Weight Regain After Incretin TreatmentThe Incretin Mirage: Epigenetic Memory as a Potential Driver of Post-Treatment Weight Regain.

🥉 Top 5% JournalArticle

2 days ago • Diabetologia

GPCRVP score reliably predicts how human GLP1R variants affect receptor functionThe GPCRVP score reliably predicts the impact of GLP1R human variants on receptor function.

🥈 Top 2% JournalArticle

2 days ago • Diabetes, obesity & metabolism

Heart and kidney benefits and safety of Finerenone, SGLT2 inhibitors, Semaglutide, and their combination in diabetic kidney diseaseComparative Cardiorenal Efficacy and Safety of Finerenone, SGLT2 Inhibitors, Semaglutide and Their Combination in Diabetic Kidney Disease.

Article

2 days ago • AIDS (London, England)

Semaglutide’s effects on hidden heart health issues in people with HIVEffects of semaglutide on subclinical cardiovascular health in people with HIV.

Article

2 days ago • JCEM case reports

Glucagon-like peptide-1 receptor drugs as add-on treatment for hard-to-treat high blood fat after repeated pancreas inflammationGlucagon-like peptide-1 receptor agonists as adjunctive therapy in refractory hypertriglyceridemia following recurrent pancreatitis.

Case Reports

2 days ago • World journal of transplantation

New approaches to weight management after liver transplant using hormone receptor treatmentsRedefining weight management after liver transplantation with glucagon-like peptide one and gastric inhibitory polypeptide receptor agonists.

📖 Top 50% JournalArticle

2 days ago • Childhood obesity (Print)

Nutritional Deficiencies, Health Issues, and Diet Support in Children Taking GLP-1 MedicinesNutritional Deficiencies, Complications, and Nutrition Therapy/Counseling in Pediatric Patients Using GLP-1 Receptor Agonists.

📖 Top 30% JournalArticle

2 days ago • BMJ open

Semaglutide as an additional treatment for obesity in teens taking antipsychotic drugs: plan for a first feasibility studySemaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.

📖 Top 20% JournalClinical Trial Protocol

2 days ago • JCEM case reports

Long-term weight loss over 100 kg using step-by-step hormone-based treatment in Prader-Willi syndromeSustained weight loss exceeding 100 kg with sequential incretin-based therapy in Prader-Willi syndrome.

Case Reports

← prevpage 1 of 14next →